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REVIEWS
Abstract: Anemia is a common, but underestimated and undertreated, complication of patients
with cancer receiving chemo- or radiotherapy, and negatively affects their quality of life (QoL).
Erythropoietic proteins (EPS) offer an effective treatment of cancer anemia and ameliorate
QoL, although their use requires the correct targeting of hemoglobin increase to avoid
thromboembolic complications. Currently the effort is focused on offering patients this effective
treatment with reduced frequency of administration. Higher weekly single doses of recombinant
human Epo (rHuEpo) either alpha or beta, instead of three times per week, have been proposed
for the treatment. The pharmacokinetic and pharmacodynamic characteristics of the
hyperglycosylated protein darbepoetin alpha permit even longer intervals between
administrations. Every other week or every three weeks schedules have shown results
(erythropoietic response, reduction of transfusion requirements, and improvement of QoL)
comparable with those of weekly rHuEpo.
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Introduction
Anemia is a frequent complication in patients with cancer and affects quality of life
(QoL) (Cella 1997; Harper and Littlewood 2005) in at least 50%. Correct investigation
of the reasons underlying anemia is mandatory for an adequate treatment (Figure 1).
A recent large survey (Ludwig et al 2004) has shown that prevalence and incidence
were 39.3% of 14 912 enrolled and 57.3% of 13 628 analyzed patients respectively.
Only 38.9% received a treatment of either transfusions or replacement therapy
including recombinant human Epo (rHuEpo). Therefore an adequate treatment is not
adopted in the majority patients with anemia of cancer.
A major step in the evaluation of anemia of chronic disorders, including cancer,
was the recognition that erythropoietin production is often blunted and serum level
inadequate to the degree of hemoglobin decrease because of toxicity, especially when
platinum is used in therapy, or the disease itself (Figure 1). Therefore, the availability
of rHuEpo alpha and beta, and successively darbepoetin alpha, has offered an effective
alternative to red cell transfusion in this setting. Bohlius and colleagues (2005) carried
out a metanalysis of 27 randomized controlled trials, involving 3953 patients, that
compared the use of rHuEpo and darbepoetin (plus transfusion if needed) with
observation until red blood cell transfusion was required. This study was recently
updated (Bohlius et al 2006) to include 57 trials with 9353 patients. The analysis of
data indicates that administration of EPS reduces the relative risk for blood
transfusions and the number of units transfused in cancer patients. For patients with
baseline hemoglobin below 12 g/dL (mild anemia) there is strong evidence of
improved hematological response and suggestive evidence of amelioration of QoL.
On the other hand, the relative risk for thromboembolic complications increases by
the treatment, while it remains uncertain whether and how rHuEpo and darbepoetin
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affect tumor response and overall survival. As for the disease
outcome, the conclusion reflects the somewhat divergent
results of a large randomized double blind versus placebo
study suggesting a possible better outcome in patients treated
with rHuEpo (Littlewood et al 2001), and those of two
different studies that have shown a risk of worst outcome of
cancer disease in patients treated with rHuEpo (Henke et al
2003; Leyland-Jones 2003). The expression of Epo receptor
(EpoR) has been demonstrated on several nonerythroid
tumor cells (Arcasoy et al 2005), but this does not invariably
translate into the receptor activation. Moreover it has been
shown that antibodies currently used in immunoblotting and
immunostaining techniques lack specificity (Elliott et al
2006), therefore the results should be evaluated with caution.
American Society of Hematology/American Society of
Clinical Oncology (ASCO) (Rizzo et al 2002), National
Comprehensive Cancer Network (NCCN) (2006), and
European Organisation for Research and Treatment of Cancer
(EORTC) (Bokemeyer et al 2004) proposed guidelines for the
use of erythropoietic proteins (EPS) in anemia of cancer. These
indicate that scope of the treatment is not only the erythropoietic
response (hemoglobin increase), but also the improvement of
QoL, negatively affected by the anemia, and prevention of
transfusion. The target hemoglobin level should be 12–13 g/
dL in order to reduce the risk of hypertension and
thromboembolic events associated with this therapy
(Bokemeyer et al 2004). However the efficacy of EPS relies
on the presence of adequate iron availability for the necessity
of erythropoiesis, therefore preliminary evaluation and
monitoring of transferrin saturation are mandatory. If
transferring saturation is ≤20% intravenous should be
administered (Auerbach et al 2004)
The spectrum of EPS includes a large variety of products,
such as erythropoietin delta (Deicher and Horl 2004) and
omega (Bren et al 2002), with registration limited to anemia
of kidney failure, while pegylated Epo beta (Osterborg et al
2004) and a pegylated synthetic peptide, Hematide (Stead
et al 2006), are still under clinical evaluation. The only
approved and currently marketed EPS for treatment of
anemia in cancer patients are rHuEpo alpha and beta, and
darbepoetin alpha. Data on rHuEpo are briefly mentioned
in this review, which will focus especially on the activity of
darbepoetin in the treatment of patients with cancer anemia.
rHuEpo
Treatment with EPS in the setting of anemia of chronic
disorders, including cancer, requires higher doses (3- to 4-
fold) than in the treatment of anemia of kidney failure, due
to the inhibition of endogenous Epo production, of bone
marrow activity, or both. Therefore a typical schedule of
150 U/Kg (10 000U) of rHuEpo three times per week with
rHuEpo alpha or beta is adopted in cancer patients instead
of 40–50 ml/Kg used in chronic kidney failure. Response
rate varies largely in relation to the disease. Commonly
hemoglobin levels improve in 25% to 30% of patients with
myelodysplastic syndrome (MDS) (Alessandrino et al.
2002), but in subgroups of patients with favourable
characteristics (International Prognostic Scoring System
[IPSS] low/intermediate 1 risk, reduced or no transfusion
support, endogenous Epo levels <200 mU/ml) this rate can
increasee to 50% with daily (ICSG 1998; Alessandrino et
al 2002) or every other day (Terpos et al 2003)
administrations of 10 000 U. Hellstrom-Lindberg and
colleagues (1998) demonstrated that the percentage of
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responders may increase if rHuEpo is used in combination
with granulocyte-colony stimulating factor (G-CSF), a result
recently confirmed by Balleari and colleagues (2005), and
this protocol proved to be effective also in patients with
higher endogenous Epo levels (up to 500m U/mL). In the
MDS setting, it is particularly important to define correctly
the criteria of response to evaluate the efficacy of treatment.
A revised version has recently been published by the
International Working Group (Cheson et al 2006). In patients
with nonmyeloid malignancies, including non-Hodgkin
lymphoma and multiple myeloma (MM), response is
obtained in 50% to 70 % of patients (Rizzo et al 2002),
with the highest response rate in MM. Gabrilove and
colleagues (2001) reported that a single weekly dose (QW)
of rHuEpo alpha (40 000–60 000U) was as effective as the
three times per week protocol, a result confirmed by others
(Shasha et al 2003; Chang et al 2005; Witzig et al 2005).
Similarly, QW dosing (30 000U) (Cazzola et al 2003) of
rHuEpo beta are as effective as 10 000 U x 3 per week.
Henry and colleagues (2006) reported that a further
extension of the interval between administration of rHuEpo
alpha using 80 000 U Q2W was as effective as 40 000 QW
with comparable safety.
Whether the measurement of endogenous Epo levels is
a useful tool to predict the response in patients with solid
cancer or lymphoproliferative disorders is questionable
(Littlewood et al 2003; Ludwig et al 2004). These are
inappropriately low in approximately 25% of all patients
with MM, and increase to 50% in patients with stage III
disease and 60% in those with renal impairment (Beguin et
al 1992). Moreover, in some patients bone marrow
infiltration participate to the poor response to rHuEpo
(Beguin 1995).
In conclusion rHuEpo is convenient and effective
treatment capable of reducing transfusion support,
increasing hemoglobin level, and improving QoL.
Darbepoetin alpha
Darbepoetin alpha is a novel hyperglycosilated
erythropoietic protein that, in comparison with rHuEpo
alpha, contains 5 N-linked carbohydrate chains versus 3 and
22 sialic acid residues versus 14. These characteristics
determine a 3 times longer half-life (25.3 h vs 8.45 h), which
increases in vivo biological activity in a murine model (Egrie
and Browne 2001), and permits less frequent
administrations. The roles of carbohydrate and sialic acid
residues in determining the pharmacokinetics and
pharmacodynamics of darbepoetin alpha have been
elucidated by Elliot and colleagues (2004). Although less
effective than rHuEpo in vitro in inducing colony-forming
unit-erythroid proliferation (due to sialic acid residues), the
longer half life confers an advantage in vivo, and the reduced
affinity for EpoR further participates to maintain
erythropoietic concentrations of darbepoetin over the time.
A QW administration of darbepoetin is sufficient for
sustained stimulation of erythropoiesis. The percentage of
cancer patients with hematopoietic response (hemoglobin
>2 g/dL or >12 g/dL in the absence of red blood cell [RBC]
transfusion) is dose-related, and time to hemoglobin
response reduced compared with three times per week
rHuEpo administration (Smith et al 2001; Glaspy et al 2002).
Maximum concentration (Cmax) is reached at week 2 after
chemotherapy, when the pool of erythroid cells is likely to
be reduced as a consequence of chemotherapy
(Heatherington et al 2001). This suggests that the clearance
of darbepoetin is possibly due to binding to EpoR expressed
on erythroid progenitor and precursor cells (Glaspy et al
2005). Finally, there is a trend toward increasing serum
concentration of darbepoetin over time, as at cycle 3
concentration was doubled compared with cycle 1. When
tested in a randomized study versus placebo in patients with
lung cancer (Vasteenkiste et al 2002), QW 150 µg
darbepoetin reduced transfusion support (27% vs 52%) and
increased hematopoietic response (66% vs 24%). Similar
results were reported by Hedenus and colleagues. (2003) in
patients with non-Hodgkin lymphomas, and these authors
observed a response to darbepoetin in 69% of patients with
basal serum Epo <100 mU/mL versus 44% in those with
basal values >100mU/mL. QoL also improved, as shown
by a Functional Assessment of Cancer Therapy-Fatigue
(FACT-F) score increased in 56% of patients treated with
darbepoetin and 44% in the placebo group, although the
difference was not significant. Recently Littlewood and
colleagues (2006) confirmed the efficacy of darbepoetin in
ameliorating fatigue and QoL in patients with
lymphoproliferative disorders, in a multicenter randomized
trial.
Currently in the QW schedule, darbepoetin is
administered at the dose of 2.25 µg/Kg (150 mg fixed dose),
to be increased to 4.50 µg/Kg (300 µg fixed dose) if response
is not observed at week four.
Darbepoetin (150 µg increased to 300 µg if no response
is observed) determines a substantial response also in
patients with low-risk MDS (Musto et al 2005; Patton et al
2005) and may offer the advantage of less frequent
administrations. In a recent series of 66 patients with low-Therapeutics and Clinical Risk Management 2007:3(2) 272
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intermediate 1 risk according to IPSS, Mannone and
colleagues (2006) obtained an overall erythroid response
of 71%, comparable with that observed in patients treated
with the rHuEpo alpha plus G-CSF combination.
Darbepoetin every-other- week
The pharmacokinetic characteristics of the Darbepoetin
suggest that Q2W or longer intervals between
administrations are made possible. In an open-label study,
Vadhan-Raj and colleagues (2003) evaluated the ability of
darbepoetin alpha to reverse chemotherapy-induced anemia
in cancer patients, induce changes in fatigue and functional
capacity and their relation to hemoglobin increase in patients
with hemoglobin ≤11 g/dL with nonmyeloid malignancy
receiving multicycle chemotherapy. Darbepoetin alpha was
administered at a starting dosage of 3 µg/kg Q2W for up to
eight doses (16 weeks). The interim analysis included a total
of 1174 patients: mean increase in hemoglobin was 1.7 g/
dL (ITT analysis) and 2.1 g/dL for those patients receiving
the full 16 weeks of therapy. The Kaplan-Meier estimate of
the proportion of subjects with a hematopoietic response
(increase in hemoglobin ≥2 g/dL and/or ≥12 g/dL) was 84%.
To summarize the results of this study: a) darbepoetin
determined an hemoglobin response (greater in patients with
hemoglobin <10 g/dL) during treatment; b) the FACT-F
subscale score increased by a mean of 6.8 points (26%)
during the study; c) improvements in fatigue score paralleled
the increases observed in hemoglobin. In conclusion the
efficacy of the Q2W regimen of darbepoetin alpha is no
different from that of weekly or three times per week
rHuEpo. Glaspy and colleagues (2002) tested the
administration of darbepoetin in a randomized multi-arm
study in which different doses of darbepoetin (3 µg/kg, 5 µg/
kg, 7 µg/kg, 9 µg/kg) Q2W were given to patients on
chemotherapy, and compared with the activity of a fixed
weekly dose (40 000) of rHuEpo alpha. 60 000 U weekly
could be used if hemoglobin increase was <1 g/dL. The study
showed that darbepoetin Q2W is as effective as rHuEpo
QW, and doses of darbepoetin higher than 5 µg/kg do not
increase the response. The feasibility of Q2W approach was
confirmed by Patton and colleagues (2004) in a retrospective
observational cohort study in which patients with
chemotherapy-induced anemia received darbepoetin 100 µg/
kg QW, darbepoetin 200 µg/kg Q2W or rHuEpo (40 000 U
QW), and by other authors (Schwartzberg et al 2004; Senecal
et al 2005; Waltzman et al 2005).
Herrington and colleagues (2005) derived data from
1444 patients treated with darbepoetin alpha and 1341 with
epoetin alpha. The most common initial dosages were 200 µg
Q2W for darbepoetin alpha (61%), and 40 000 U QW
epoetin alpha (72%). The dosage was escalated for 22% of
darbepoetin alpha recipients
 and 23% of epoetin alpha
recipients at a median of six weeks after the initial dose.
The mean change from baseline in hemoglobin concentration
after 12 weeks of therapy was similar for both
 groups, as




The possibility to further prolong the interval between
administrations of darbepoetin in patients with cancer
chemotherapy-induced anemia has also been explored.
Kotasek and colleagues (2003), in a dose finding (from
4.5 µg/kg to 15 µg/kg by 2.5 µg/kg steps) placebo-controlled
study, observed that at all doses given darbepoetin Q3W
reduced transfusion requirements compared with placebo,
and hemoglobin increase was dose-dependent, with an
increase ≥1 g/dL at doses of 6.75 mg/kg or greater. Fact-F
fatigue score also improved with increasing hemoglobin
concentration (p=0.0023), and safety profile was comparable
in darbepoetin- and placebo-treated patients.
Glaspy and coworkers (2005) studied whether timing
in respect to chemotherapy influences efficacy of
darbepoetin Q3W. A dose of 6.75 µg/kg Q3W was
administered synchronously (starting on chemotherapy day
1, patients 38) or asynchronously (starting on chemotherapy
day 15, patients 43) with concurrent chemotherapy Q3W
(platinum- and nonplatinum-based regimens) in patients
with nonmyeloid malignancies (40% breast cancer). Primary
endpoints were mean change in hemoglobin after 6 weeks
from baseline and proportion of patients with hemoglobin
increase from baseline were 1 g/dL. Secondary endpoints
at the entire treatment period (16 weeks) were the proportion
of patients with hemoglobin increase of hemoglobin >2 g/
dL or a level of >12 g/dL in the absence of RBC transfusion,
time to erythropoietic response, proportion of patients who
had a RBC transfusion from week 5 to end of treatment.
The overall erythropoietic response was 74%, and there was
no difference between groups in the proportion of patients
who achieved an increase in hemoglobin equal to or >1 g/
dL, and time to erythropoietic response. Only 19% of
patients required transfusion support. These results seem to
be comparable with those obtained with darbepoetin QW
administration. Two data suggest that the binding to receptor
plays a role in the clearance of EPS in patients with
chemotherapy-induced anemia: a) pharmacokinetic analysisTherapeutics and Clinical Risk Management 2007:3(2) 273
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carried out in a subset of patients indicated that endogenous
erythropoietin concentration increases and lasts for
approximately 1 week following chemotherapy
administration; b) synchronous administration of
darbepoetin alpha was associated with a 1.3-fold increase
in the darbepoetin alpha area-under-the-curve compared
with asynchronous administration. The feasibility of the
Q3W schedule has been confirmed by Boccia and colleagues
(2006)
A direct comparison between fixed 500 µg Q3W at fixed
dose and 2.25 µg/kg QW was carried out by Canon and
colleagues (2006) in a non inferiority study active-controlled
phase III study, in patients with nonmyeloid malignancies.
The incidence of transfusion was 19% of 353 patients in
the group treated with 500 mg Q3W and 28% of 352 patient
in the QW group. The target hemoglobin level was reached
in a similar proportion of patients and increase in FACT-F
score was also superimposable, without differences in
toxicity.
An Q4W administration is probably possible using an
adequate dosing of darbepoetin (Smith et al 2003). A
hyperglycosylated analog of darbepoetin (AMG 114) with
longer half life is currently in phase I clinical study.
Conclusions
Anemia is a common, underestimated and undertreated
complication of cancer, especially in patients treated with
chemotherapy. Provided that other factors, especially iron,
are in sufficient amount to support their activity, EPS offer
a simple, effective and generally safe treatment of anemia.
The targets of this treatment should be: a) reduction or,
possibly, elimination of transfusion support (therefore the
beginning of treatment should not be delayed if the patient’s
hemoglobin levels is 10–11 g/dL; b) an adequate hemoglobin
level (12–13 g/dL) that also would also improve QoL could
be improved in patients with cancer, but avoiding higher
values that could expose the patient to thromboembolic
complication. The guidelines released by EORTC, NCCN,
and ASCO are useful tools for these purposes.
From the large amount of data available in the literature
it can be concluded that darbepoetin is as effective as
rHuEpo (60% to 80% of patients respond to therapy) in
stimulating erythropoiesis in patients with cancer.
Pharmakokinetic characteristics make darbepoetin ideal for
a reduced frequency of administration and more convenient
for the patient by adjusting dosage and frequency to reach
and maintain the target hemoglobin level. In consideration
that chemotherapy is most commonly given every three
week, a supplemental Biologics License Application has
been submitted by the producer to the Food and Drug
Administration for Q3W administration. The European
Agency (EMEA) has granted darbepoetin approval for
extended dosing once every three weeks interval in the
treatment of cancer chemotherapy-induced anemia in 2004.
In this setting there is no evidence that 500 µg are more
effective than 300 µg in the Q3W schedule because a direct
comparison of these doses is not available.
Less frequent dosing of rHuEpo, either alpha or beta,
than 3 times per week proved to be effective, and adequate
dosing could make the Q3W interval possible even with
these erythropoietic agents.
The preliminary data of efficacy of the new pegylated
Epo beta (Continuous Erythropoiesis Stimulating Activity
– CERA) (Osterborg et al 2004) in a Q3W administration,
and the pharmacokinetics of hematide, confirm the trend
toward a reduced frequency of administration of
erythropoietic proteins. The development of drugs targeting
the hypoxia-inducible factor through the inactivation of the
degradation enzyme prolyl-4-hydroxylase and with different
(oral) route of administration are underway and could offer
new perspectives in the control of anemia of cancer patients.
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